Quantitative proteomics analysis of medullary thyroid carcinoma

Medullary thyroid cancer (MTC) accounts for less than 5% of all thyroid cancers, and it is a rare neuroendocrine tumor which derives from calcitonin-secreting thyroid C cells.Given the underlying mechanism involved in MTC remain unclear, the development and the specific pathways of MTC require further investigation.here we employed the application of TMT6plex-based LC-MS/MS to identify and analyze the novel differentially-expressed proteins(DEPs) from MTC patients, To our best knowledge, it is the first study to comprehensively investigate the molecular mechanisms of MTC by proteomics technology from Chinese MTC patients’ tissues, and these DEPs identified in our study will provide a better understanding of the underlying pathophysiology of MTC, as well as may provide potential therapeutic targets for patients with MTC.

髓样甲状腺癌（Medullary thyroid cancer, MTC）占所有甲状腺癌的比例不足5%，是一种起源于分泌降钙素的甲状腺C细胞的罕见神经内分泌肿瘤。鉴于目前髓样甲状腺癌的发病机制尚未明确，其发生发展及具体信号通路仍有待进一步研究。本研究采用基于TMT6plex标记的液相色谱-串联质谱（LC-MS/MS）技术，对髓样甲状腺癌患者组织中的差异表达蛋白（differentially-expressed proteins, DEPs）进行鉴定与分析。据我们所知，本研究是首个利用蛋白质组学技术对中国髓样甲状腺癌患者的组织样本开展MTC分子机制全面探究的研究。本研究鉴定得到的差异表达蛋白，不仅有助于进一步阐明MTC潜在的病理生理机制，同时也可为MTC患者提供潜在的治疗靶点。